Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HER2-positive Breast Cancer: early-phase trial registry
28 of 59 indexed HER2-positive Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #241 of 28,707 conditions by registered trial count.
59 US clinical trials · 28 currently recruiting · #241 of 28,707 conditions by registered trial count
HER2-positive Breast Cancer: 59 US clinical trials tracked, 28 recruiting.
HER2-positive Breast Cancer is the subject of 59 registered US clinical trials on ClinicalTrials.gov, 28 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 46 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 7 of these trials.
Enrollment posture brief
Registry condition her2-positive-breast-cancer
OPEN 28 | RECR 47% | LATE 4 | EARLY 46 | RANK #241 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Metastatic Lung Non-Small Cell Carcinoma (48% recruiting · 40 trials)
HER2-positive Breast Cancer lists 28 open slots (47% of 59 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HER2-positive Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HER2-positive Breast Cancer is recruiting above its size-band peers.
28 of 59 indexed trials (47.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of HER2-positive Breast Cancer trials is spread across many organizations.
H. Lee Moffitt Cancer Center and Research Institute accounts for 7 of 59 trials (11.9%). 38 distinct sponsors appear on at least one study for this condition label.
-
Typical HER2-positive Breast Cancer enrolment sits around 63 participants.
Median target enrolment is 63 among the 59 trials that report a genuine target (sentinel values excluded). 33 of those (55.9%) plan for fewer than 100 participants.
-
HER2-positive Breast Cancer research is mostly interventional.
55 interventional and 4 observational studies make up this index (93.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
59 total, page 1 of 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
QuantumLeap Healthcare Collaborative
NCT01042379
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
NRG Oncology
NCT05705401
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Dana-Farber Cancer Institute
NCT04893109
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Dana-Farber Cancer Institute
NCT04569747
Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer
University of Miami
NCT06123988
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Iambic Therapeutics
NCT06253871
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Brigham and Women's Hospital
NCT04030507
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Baylor Breast Care Center
NCT05020860
Study of Screening Brain MRIs in Stage IV Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT05115474
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
MedSIR
NCT06172127
A Study of Surgery and Radiotherapy in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT07053085
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Mersana Therapeutics
NCT05514717
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Jazz Pharmaceuticals
NCT07102381
PRE-I-SPY Phase I/Ib Oncology Platform Program
QuantumLeap Healthcare Collaborative
NCT05868226
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
NCT06439693
TRUDI: TDXD+Durva in HER2+/Low IBC
Filipa Lynce, MD
NCT05795101
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
Memorial Sloan Kettering Cancer Center
NCT07459673
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
H. Lee Moffitt Cancer Center and Research Institute
NCT05325632
HER-2 B Cell Peptide Vaccine
Pravin T.P Kaumaya
NCT06414733
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute
NCT04588545
HER2 Vaccine for Locally Advanced Breast Cancer
Pravin T.P Kaumaya
NCT06949410
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Ruth O'Regan
NCT04886531
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
Alison Stopeck
NCT06220214
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT05378464
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
University of Illinois at Chicago
NCT06441890
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
University of Alabama at Birmingham
NCT04332588
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
H. Lee Moffitt Cancer Center and Research Institute
NCT05809752
NearWave Optical Molecular Monitoring
Indiana University
NCT06744465
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
NCT05132582
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
Alliance Foundation Trials
NCT02947685
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
NCT03975647
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Enliven Therapeutics
NCT06328738
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
Hoffmann-La Roche
NCT05593094
MARGetuximab Or Trastuzumab (MARGOT)
Dana-Farber Cancer Institute
NCT04425018
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
NCT02326974
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
University of Texas Southwestern Medical Center
NCT03747120
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Brigham and Women's Hospital
NCT04899908
A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging
Northwestern University
NCT02993198
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03384914
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Dana-Farber Cancer Institute
NCT05721248
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
City of Hope Medical Center
NCT01730833
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03387553
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
Adrienne G. Waks
NCT06100874
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
City of Hope Medical Center
NCT03696030
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
Memorial Sloan Kettering Cancer Center
NCT05036252
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
NCT03179904
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
Fox Chase Cancer Center
NCT03125928
Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
University of Washington
NCT03738553
Omission of Radiation in Patients With Her-2 Positive Breast Cancer
University of Kansas Medical Center
NCT03460067
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
City of Hope Medical Center
NCT02226276
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 28 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on HER2-positive Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HER2-positive Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HER2-positive Breast Cancer page
59 registered trials, 28 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 28 HER2-positive Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- H. Lee Moffitt Cancer Center and Research Institute sponsors the most HER2-positive Breast Cancer trials on record, review their full trial history before evaluating a specific study. See H. Lee Moffitt Cancer Center and Research Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HER2-positive Breast Cancer condition card totals 59 registered trials; most-linked intervention Trastuzumab; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.